In the last trading session, 2.8 million Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares changed hands as the company’s beta touched 0.97. With the company’s per share price at $0.43 changed hands at $0.02 or 6.68% during last session, the market valuation stood at $1.65M. GLMD’s last price was a discount, traded about -3197.67% off its 52-week high of $14.18. The share price had its 52-week low at $0.35, which suggests the last value was 18.6% up since then. When we look at Galmed Pharmaceuticals Ltd’s average trading volume, we note the 10-day average is 33510.0 shares, with the 3-month average coming to 66.48K.

Analysts gave the Galmed Pharmaceuticals Ltd (GLMD) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended GLMD as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Galmed Pharmaceuticals Ltd’s EPS for the current quarter is expected to be -$0.3.

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) trade information

Instantly GLMD was in green as seen at the end of in last trading. With action 23.03%, the performance over the past five days has been green. The jump to weekly highs of 0.4343 on Monday, 11/20/23 added 6.68% to the stock’s daily price. The company’s shares are showing year-to-date downside of -94.21%, with the 5-day performance at 23.03% in the green. However, in the 30-day time frame, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) is 4.05% up. Looking at the short shares, we see there were 10970.0 shares sold at short interest cover period of 0.08 days.

The consensus price target for the stock as assigned by Wall Street analysts is $4.00, meaning bulls need an upside of 89.25% from its current market value. According to analyst projections, GLMD’s forecast low is $4.00 with $4.00 as the target high. To hit the forecast high, the stock’s price needs a -830.23% plunge from its current level, while the stock would need to soar -830.23% for it to hit the projected low.

Galmed Pharmaceuticals Ltd (GLMD) estimates and forecasts

Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Galmed Pharmaceuticals Ltd will rise 90.50%, while the growth in revenue is estimated to hit 78.00% for the next quarter.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 6.23%.

GLMD Dividends

Galmed Pharmaceuticals Ltd is expected to release its next quarterly earnings report between November 21 and December 06.